245 related articles for article (PubMed ID: 30344996)
1. Real-world effectiveness of long-acting antipsychotic treatments in a nationwide cohort of 3957 patients with schizophrenia, schizoaffective disorder and other diagnoses in Quebec.
Stip E; Lachaine J
Ther Adv Psychopharmacol; 2018 Nov; 8(11):287-301. PubMed ID: 30344996
[TBL] [Abstract][Full Text] [Related]
2. Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge.
Marcus SC; Zummo J; Pettit AR; Stoddard J; Doshi JA
J Manag Care Spec Pharm; 2015 Sep; 21(9):754-68. PubMed ID: 26308223
[TBL] [Abstract][Full Text] [Related]
3. Treatment patterns in Medicaid patients with schizophrenia initiated on a first- or second-generation long-acting injectable versus oral antipsychotic.
Pilon D; Joshi K; Tandon N; Lafeuille MH; Kamstra RL; Emond B; Lefebvre P
Patient Prefer Adherence; 2017; 11():619-629. PubMed ID: 28356723
[TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness of risperidone long-acting injectable vs first-generation antipsychotic long-acting injectables in schizophrenia: results from a nationwide, retrospective inception cohort study.
Nielsen J; Jensen SO; Friis RB; Valentin JB; Correll CU
Schizophr Bull; 2015 May; 41(3):627-36. PubMed ID: 25180312
[TBL] [Abstract][Full Text] [Related]
5. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.
Pilon D; Tandon N; Lafeuille MH; Kamstra R; Emond B; Lefebvre P; Joshi K
Clin Ther; 2017 Oct; 39(10):1972-1985.e2. PubMed ID: 28919292
[TBL] [Abstract][Full Text] [Related]
6. Health resource utilization and cost before versus after initiation of second-generation long-acting injectable antipsychotics among adults with schizophrenia in Alberta, Canada: a retrospective, observational single-arm study.
Wong KO; Klarenbach SW; Martins KJB; Chue P; Dursun SM; Snaterse M; Guigue A; So H; Luu H; Vu K; Richer L
BMC Psychiatry; 2022 Jul; 22(1):444. PubMed ID: 35780116
[TBL] [Abstract][Full Text] [Related]
7. Healthcare resource utilization of second-generation long-acting injectable antipsychotics in schizophrenia: risperidone versus paliperidone palmitate.
Joshi K; Pan X; Wang R; Yang E; Benson C
Curr Med Res Opin; 2016 Nov; 32(11):1873-1881. PubMed ID: 27479694
[TBL] [Abstract][Full Text] [Related]
8. "Impact of drug-reimbursement policies on prescribing: A case-study of a newly marketed long-acting injectable antipsychotic among relapsed schizophrenia patients".
Jackson JW; Fulchino L; Rogers J; Mogun H; Polinski J; Henderson DC; Schneeweiss S; Fischer MA
Pharmacoepidemiol Drug Saf; 2018 Jan; 27(1):95-104. PubMed ID: 29168261
[TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness of long-acting risperidone in New Zealand: a report of resource utilization and costs in a 12-month mirror-image analysis.
Carswell C; Wheeler A; Vanderpyl J; Robinson E
Clin Drug Investig; 2010; 30(11):777-87. PubMed ID: 20712387
[TBL] [Abstract][Full Text] [Related]
10. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
[TBL] [Abstract][Full Text] [Related]
11. First-generation
Stone JM; Roux S; Taylor D; Morrison PD
Ther Adv Psychopharmacol; 2018 Dec; 8(12):333-336. PubMed ID: 30524701
[TBL] [Abstract][Full Text] [Related]
12. Impact of switching to long-acting injectable antipsychotics on health services use in the treatment of schizophrenia.
Lachaine J; Lapierre ME; Abdalla N; Rouleau A; Stip E
Can J Psychiatry; 2015 Mar; 60(3 Suppl 2):S40-7. PubMed ID: 25886679
[TBL] [Abstract][Full Text] [Related]
13. Real-World Evidence of the Clinical and Economic Impact of Long-Acting Injectable Versus Oral Antipsychotics Among Patients with Schizophrenia in the United States: A Systematic Review and Meta-Analysis.
Lin D; Thompson-Leduc P; Ghelerter I; Nguyen H; Lafeuille MH; Benson C; Mavros P; Lefebvre P
CNS Drugs; 2021 May; 35(5):469-481. PubMed ID: 33909272
[TBL] [Abstract][Full Text] [Related]
14. Treatment Patterns, Healthcare Resource Utilization and Costs Among Schizophrenia Patients Treated with Long-Acting Injectable Versus Oral Antipsychotics.
Shah A; Xie L; Kariburyo F; Zhang Q; Gore M
Adv Ther; 2018 Nov; 35(11):1994-2014. PubMed ID: 30269292
[TBL] [Abstract][Full Text] [Related]
15. Off-label long acting injectable antipsychotics in real-world clinical practice: a cross-sectional analysis of prescriptive patterns from the STAR Network DEPOT study.
D'Agostino A; Aguglia A; Barbui C; Bartoli F; Carrà G; Cavallotti S; Chirico M; Ostinelli EG; Zangani C; Martinotti G; Ostuzzi G;
BMC Psychiatry; 2022 Jun; 22(1):442. PubMed ID: 35773631
[TBL] [Abstract][Full Text] [Related]
16. Healthcare resource utilization and costs before and after long-acting injectable antipsychotic initiation in commercially insured young adults with schizophrenia.
Fu AZ; Pesa JA; Lakey S; Benson C
BMC Psychiatry; 2022 Apr; 22(1):250. PubMed ID: 35395757
[TBL] [Abstract][Full Text] [Related]
17. Adherence, persistence, and inpatient utilization among adult schizophrenia patients using once-monthly versus twice-monthly long-acting atypical antipsychotics.
Pilon D; Alcusky M; Xiao Y; Thompson-Leduc P; Lafeuille MH; Lefebvre P; Benson C
J Med Econ; 2018 Feb; 21(2):135-143. PubMed ID: 28895766
[TBL] [Abstract][Full Text] [Related]
18. Baseline results from the European non-interventional Antipsychotic Long acTing injection in schizOphrenia (ALTO) study.
Llorca PM; Bobes J; Fleischhacker WW; Heres S; Moore N; Bent-Ennakhil N; Sapin C; Loze JY; Nylander AG; Patel MX
Eur Psychiatry; 2018 Aug; 52():85-94. PubMed ID: 29734130
[TBL] [Abstract][Full Text] [Related]
19. Risk Factors, Incidence, and Outcomes of Neuroleptic Malignant Syndrome on Long-Acting Injectable vs Oral Antipsychotics in a Nationwide Schizophrenia Cohort.
Guinart D; Taipale H; Rubio JM; Tanskanen A; Correll CU; Tiihonen J; Kane JM
Schizophr Bull; 2021 Oct; 47(6):1621-1630. PubMed ID: 34013325
[TBL] [Abstract][Full Text] [Related]
20. Readmissions, costs, and duration to subsequent outpatient visit after hospital discharge among Medicaid beneficiaries utilizing oral versus long-acting injectable antipsychotics in bipolar disorder or schizophrenia.
Tidmore LM; Keast SL; Waters HC; Pareja KL; Cothran T; Skrepnek GH
Curr Med Res Opin; 2022 Sep; 38(9):1621-1630. PubMed ID: 35833696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
